highly significantp=0.0005
Regarding stage group, our study out of 36 resected cases revealed that combined MSH6 & PMS2 loss prevalent in stage III tumors (54.5%), followed by stage II tumors (45.5%), with a highly significant correlation combined markers loss between and III/II stages (p=0.0005).